Skip to main content

Regulatory and Washington

  • Mead Johnson retests Enfamil batch and affirms no contamination

    GLENVIEW, Ill. — Mead Johnson Nutrition over the holidays conducted a new round of testing on samples of a batch of Enfamil Premium Newborn powdered formula related to a Food and Drug Administration investigation.

    Drawn from samples parallel to those being tested by public health officials and following the same methodology, the new testing did not detect any presence of Cronobacter (Enterobacter sakazakii), the company stated.

  • FDA panel to review Qnexa in February 2012

    MOUNTAIN VIEW, Calif. — The Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee is set to review an investigational treatment for obesity.

    Biopharmaceutical company Vivus said the panel will review its new drug application for Qnexa on Feb. 22, 2012.

    Meanwhile, the FDA will complete its review of the NDA for Qnexa on April 17, 2012. The regulatory agency accepted the NDA in November after Vivus' resubmission of the NDA in October.

  • Retailers pull infant formula off shelves ahead of any possible recall

    GLENVIEW, Ill. — So far two retailers — Supervalu and Walmart — have pulled lots of Emfamil Premium Newborn powdered formula before any recall has been issued after learning of an infant's death this past weekend, according to published reports.

  • 12 for 2012

    Rather than take off for Christmas, the editors of Drug Store News took a look at the year ahead and the stories, issues and trends that will make headlines in retail pharmacy in 2012.

  • FDA warns parents to read drug facts label for liquid APAP

    SILVER SPRING, Md. — The Food and Drug Administration on Thursday urged consumers to carefully read the labels of liquid acetaminophen marketed for infants to avoid giving the wrong dose to their infants. Giving more than the recommended dose of acetaminophen can cause serious side effects and possibly death, the agency warned.

  • Amneal launches felbamate oral suspension

    BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched its generic version of a drug designed to treat seizures in adults and children with epilepsy.

    The generic drug maker said it received approval from the Food and Drug Administration on Dec. 16 for felbamate oral suspension in the 600-mg/5-mL strength. The Amneal generic is available in two sizes, 8 fl. oz./240 mL and 16 fl. oz./473 mL. It is a generic version of Meda Pharmaceuticals' antiepileptic Felbatol.

  • McNeil recalls Motrin tablets for reduction in efficacy nearing expiration dates

    FORT WASHINGTON, Pa. — McNeil Consumer Healthcare on Wednesday issued a voluntarily recall of certain lots of Motrin IB coated tablets from retailers. "This is not a consumer-level recall, which means that consumers do not need to dispose of or return the product," McNeil stated. 

    McNeil is recalling these products because testing of product samples showed that some caplets may not dissolve as quickly as intended when nearing their expiration date.

  • American Diabetes Association CEO to serve as National Health Council board chairman

    WASHINGTON — Larry Hausner, the CEO of the American Diabetes Association, will serve as the 2012 chairman of the National Health Council's board of directors, NHC said.

X
This ad will auto-close in 10 seconds